Press releases

(May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast an analyst meeting it is hosting on Wednesday, May 26, in conjunction with the Paris Course on Revascularization (PCR), the...

and New Orleans, LA (May 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced sub-population data from a 12-month, 117-patient study of the Enteryx procedure for patients...

and New Orleans, LA (May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced clinical trial data supporting the safety and effectiveness of the Enteryx procedure in relieving...

(May 17, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Banc of America Securities Health Care Conference 2004, which is being held May 19-21 in Las Vegas....

(May 4, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for...

(May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for...

(April 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being held May 5-7 in Miami. On...

(April 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from its clinical trial to evaluate the benefits of stenting in conjunction with embolic protection...

(April 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for its first quarter ended March 31, 2004, as well as preliminary information related to U.S. sales...

(April 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Express® Biliary...

(April 14, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2004 on Tuesday, April 20, at 9:00...

(April 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the U.S. launch of its Sentinol™ Self-Expanding Nitinol Biliary Stent System (Sentinol), which has been cleared by...

(April 7, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Precision Vascular Systems, Inc. (Precision Vascular), a privately held company located in West...

(April 5, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary results related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system and...

(April 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the European Patent Office has declared invalid a patent held by Medinol Ltd. This is the patent that Boston...

(March 31, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has concluded enrollment in its TAXUS V de novo lesion clinical trial. The Company has enrolled 1,172...

(March 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Contour SE™...

(March 25, 2004) -- Boston Scientific Corporation (NYSE: BSX) and EndoTex Interventional Systems, Inc. announced today the completion of enrollment in a carotid artery stenting clinical trial to...

(March 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent system....

(December 2, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling all Stainless Steel Greenfield® Vena Cava Filters with 12Fr Femoral Introducer...

(March 4, 2004) - Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS™ Express2™...

(March 4, 2004) - Boston Scientific Corporation (NYSE: BSX) today announced that it has completed a land purchase in Kerkrade, the Netherlands. The site will house the Company's new distribution...

(February 26, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 7th Annual Lehman Brothers' 2004 Global Healthcare Conference, which is being held March 3-5 in...

and New York, NY (February 23, 2004) -- Boston Scientific Corporation (NYSE: BSX) today hosted a meeting with analysts and investors in New York and addressed growth prospects for the Company in...

(February 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has entered into an agreement with Guidant Corporation to settle all outstanding litigation between the two...

(February 20, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has made an equity investment in -- and secured an exclusive option to purchase -- Cameron Health, Inc., a...

(February 19, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received a license for the sale of its Carotid Wallstent® Monorail® Endoprosthesis in Canada. The...

(February 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has made an equity investment in and secured an exclusive option to acquire Endoscopic Technologies Inc....

(February 17, 2004) -- Boston Scientific Corporation (NYSE: BSX) will simultaneously webcast an analyst meeting it is hosting on Monday, February 23. The meeting is scheduled to begin at 8:30 a.m....

and Maple Grove, MN (February 17, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced major plant and employment expansion plans in Minnesota, headquarters of its Cardiovascular...

(February 9, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed its purchase of the Addition Hill Corporate Center in Marlborough, Massachusetts. The site...

(February 6, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that an inspection team from the U.S. Food and Drug Administration (FDA) has completed its inspection of the...

(February 4, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the start of enrollment in the ARRIVE registry program, which plans to enroll 2,000 patients at approximately 50...

(January 30, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the United States District Court for the District of Delaware has scheduled a trial for June 2005 in the...

(January 29, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received reimbursement approval from the French government for its TAXUS™ Express2™...

(January 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2004 Merrill Lynch Pharmaceutical, Biotechnology and Medical Device Conference, which is being...

(January 22, 2004) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and the year ended December 31, 2003 on Monday,...

(January 21, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2004 Piper Jaffray Health Care Conference, which is being held January 27-29 in New York City....

(January 16, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that it has completed enrollment of a clinical trial to evaluate the benefits of stenting - in conjunction with...

(January 6, 2004) -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 22nd Annual JPMorgan Healthcare Conference, which is being held January 12-15 in San Francisco....